Halifax, Canada
Halifax, Canada

Time filter

Source Type

The invention provides compositions comprising a carrier comprising a continuous phase of a hydrophobic substance, liposomes, and a polynucleotide, and methods for using such compositions for delivering a polynucleotide to a subject.


LONDON, UK / ACCESSWIRE / February 24, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Biotechnology industry. Companies recently under review include Resverlogix, Immunovaccine, IntelliPharmaCeutics International, and Aeterna Zentaris. Get all of our free research reports by signing up at: At the close of the Canadian markets on Thursday, February 23, 2017, the Toronto Exchange Composite index ended the trading session at 15,781.20, 0.31% lower from its previous closing price. The Healthcare Index was also in the red, closing the day at 75.83, down 0.66%. Active Wall St. has initiated research reports on the following equities: Resverlogix Corporation (TSX: RVX), Immunovaccine Inc. (TSX: IMV), IntelliPharmaCeutics International Inc. (TSX: I), and Aeterna Zentaris Inc. (TSX: AEZ). Register with us now for your free membership and research reports at: Calgary, Canada headquartered Resverlogix Corp.'s stock closed the day 3.21% higher at $1.93. The stock recorded a trading volume of 27,554 shares. Resverlogix's shares have gained 6.63% in the last three months and 27.81% in the past one year. Shares of the company, which develops small molecule therapeutics for Bromodomain and ExtraTerminal inhibition, are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $1.86 is greater than its 200-day moving average of $1.74. See our research report on RVX.TO at: Halifax, Canada headquartered Immunovaccine Inc.'s stock fell 2.38%, to finish Thursday's session at $1.23 with a total volume of 105,459 shares traded. Over the last one month and the previous three months, Immunovaccine's shares have surged 80.88% and 53.75%, respectively. Furthermore, the stock has rallied 156.25% in the past one year. Shares of the company, which develops products based on its proprietary vaccine enhancement platform with a primary focus on T cell activating therapies for cancer, are trading above its 50-day and 200-day moving averages. Immunovaccine's 50-day moving average of $0.87 is above its 200-day moving average of $0.76. The complimentary research report on IMV.TO at: On Thursday, shares in Toronto, Canada-based IntelliPharmaCeutics International Inc. recorded a trading volume of 18,375 shares, which was higher than their three months average volume of 15,638 shares. The stock ended the day 7.87% lower at $2.81. IntelliPharmaCeutics Shares of the company, which researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada, are trading below its 50-day and 200-day moving averages. The stock's 50-day moving average of $3.51 is above its 200-day moving average of $3.31. Register for free and access the latest research report on I.TO at: On Thursday, shares in Summerville, South Carolina headquartered Aeterna Zentaris Inc. ended the session 0.74% higher at $4.08 with a total volume of 5,344 shares traded. Aeterna Zentaris' shares have gained 22.52% in the past one month. Shares of the company, which engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health, are trading above its 50-day moving average. Furthermore, the stock's 200-day moving average of $4.56 is greater than its 50-day moving average of $3.79. Get free access to your research report on AEZ.TO at: Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. LONDON, UK / ACCESSWIRE / February 24, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Biotechnology industry. Companies recently under review include Resverlogix, Immunovaccine, IntelliPharmaCeutics International, and Aeterna Zentaris. Get all of our free research reports by signing up at: At the close of the Canadian markets on Thursday, February 23, 2017, the Toronto Exchange Composite index ended the trading session at 15,781.20, 0.31% lower from its previous closing price. The Healthcare Index was also in the red, closing the day at 75.83, down 0.66%. Active Wall St. has initiated research reports on the following equities: Resverlogix Corporation (TSX: RVX), Immunovaccine Inc. (TSX: IMV), IntelliPharmaCeutics International Inc. (TSX: I), and Aeterna Zentaris Inc. (TSX: AEZ). Register with us now for your free membership and research reports at: Calgary, Canada headquartered Resverlogix Corp.'s stock closed the day 3.21% higher at $1.93. The stock recorded a trading volume of 27,554 shares. Resverlogix's shares have gained 6.63% in the last three months and 27.81% in the past one year. Shares of the company, which develops small molecule therapeutics for Bromodomain and ExtraTerminal inhibition, are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $1.86 is greater than its 200-day moving average of $1.74. See our research report on RVX.TO at: Halifax, Canada headquartered Immunovaccine Inc.'s stock fell 2.38%, to finish Thursday's session at $1.23 with a total volume of 105,459 shares traded. Over the last one month and the previous three months, Immunovaccine's shares have surged 80.88% and 53.75%, respectively. Furthermore, the stock has rallied 156.25% in the past one year. Shares of the company, which develops products based on its proprietary vaccine enhancement platform with a primary focus on T cell activating therapies for cancer, are trading above its 50-day and 200-day moving averages. Immunovaccine's 50-day moving average of $0.87 is above its 200-day moving average of $0.76. The complimentary research report on IMV.TO at: On Thursday, shares in Toronto, Canada-based IntelliPharmaCeutics International Inc. recorded a trading volume of 18,375 shares, which was higher than their three months average volume of 15,638 shares. The stock ended the day 7.87% lower at $2.81. IntelliPharmaCeutics Shares of the company, which researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada, are trading below its 50-day and 200-day moving averages. The stock's 50-day moving average of $3.51 is above its 200-day moving average of $3.31. Register for free and access the latest research report on I.TO at: On Thursday, shares in Summerville, South Carolina headquartered Aeterna Zentaris Inc. ended the session 0.74% higher at $4.08 with a total volume of 5,344 shares traded. Aeterna Zentaris' shares have gained 22.52% in the past one month. Shares of the company, which engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health, are trading above its 50-day moving average. Furthermore, the stock's 200-day moving average of $4.56 is greater than its 50-day moving average of $3.79. Get free access to your research report on AEZ.TO at: Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


LONDON, UK / ACCESSWIRE / February 24, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Biotechnology industry. Companies recently under review include Resverlogix, Immunovaccine, IntelliPharmaCeutics International, and Aeterna Zentaris. Get all of our free research reports by signing up at: At the close of the Canadian markets on Thursday, February 23, 2017, the Toronto Exchange Composite index ended the trading session at 15,781.20, 0.31% lower from its previous closing price. The Healthcare Index was also in the red, closing the day at 75.83, down 0.66%. Active Wall St. has initiated research reports on the following equities: Resverlogix Corporation (TSX: RVX), Immunovaccine Inc. (TSX: IMV), IntelliPharmaCeutics International Inc. (TSX: I), and Aeterna Zentaris Inc. (TSX: AEZ). Register with us now for your free membership and research reports at: Calgary, Canada headquartered Resverlogix Corp.'s stock closed the day 3.21% higher at $1.93. The stock recorded a trading volume of 27,554 shares. Resverlogix's shares have gained 6.63% in the last three months and 27.81% in the past one year. Shares of the company, which develops small molecule therapeutics for Bromodomain and ExtraTerminal inhibition, are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $1.86 is greater than its 200-day moving average of $1.74. See our research report on RVX.TO at: Halifax, Canada headquartered Immunovaccine Inc.'s stock fell 2.38%, to finish Thursday's session at $1.23 with a total volume of 105,459 shares traded. Over the last one month and the previous three months, Immunovaccine's shares have surged 80.88% and 53.75%, respectively. Furthermore, the stock has rallied 156.25% in the past one year. Shares of the company, which develops products based on its proprietary vaccine enhancement platform with a primary focus on T cell activating therapies for cancer, are trading above its 50-day and 200-day moving averages. Immunovaccine's 50-day moving average of $0.87 is above its 200-day moving average of $0.76. The complimentary research report on IMV.TO at: On Thursday, shares in Toronto, Canada-based IntelliPharmaCeutics International Inc. recorded a trading volume of 18,375 shares, which was higher than their three months average volume of 15,638 shares. The stock ended the day 7.87% lower at $2.81. IntelliPharmaCeutics Shares of the company, which researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada, are trading below its 50-day and 200-day moving averages. The stock's 50-day moving average of $3.51 is above its 200-day moving average of $3.31. Register for free and access the latest research report on I.TO at: On Thursday, shares in Summerville, South Carolina headquartered Aeterna Zentaris Inc. ended the session 0.74% higher at $4.08 with a total volume of 5,344 shares traded. Aeterna Zentaris' shares have gained 22.52% in the past one month. Shares of the company, which engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health, are trading above its 50-day moving average. Furthermore, the stock's 200-day moving average of $4.56 is greater than its 50-day moving average of $3.79. Get free access to your research report on AEZ.TO at: Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


News Article | November 1, 2016
Site: www.marketwired.com

HALIFAX, NOVA SCOTIA--(Marketwired - Nov. 1, 2016) - Immunovaccine Inc. ("Immunovaccine" or the "company") (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, today announced that Gabriela Rosu, M.D., has been named the company's first chief medical officer (CMO), effective November 7, 2016. In this newly created executive role, Dr. Rosu will oversee the strategy and execution of the company's expanding clinical portfolio of programs. She will lead the clinical efforts to develop the Company's DepoVax™-based product candidates in immuno-oncology and infectious diseases. "We have reached an exciting point at Immunovaccine, as, with the recent progress of our clinical programs, we are rapidly approaching key milestones," said Frederic Ors, Immunovaccine's Chief Executive Officer. "The clinical and commercial experience that Gabriela brings to our team will be instrumental in preparing for our expansion and validates the potential of our platform and product candidates. We are thrilled to welcome her to our team, and believe that the depth and breadth of her medical knowledge, as well as her industry track record, are tremendous assets to our organization." Dr. Rosu brings to Immunovaccine more than 15 years of broad clinical and pharmaceutical industry experience that spans the entire value chain of pharmaceutical development, from early-phase discovery to post-marketing commercialization. Most recently, Dr. Rosu was appointed the Medical Science Liaison, Haematology Oncology, at Janssen Inc., where she was responsible for the regional medical strategy implementation for targeted and immuno-modulating therapy in chronic lymphocytic leukemia (CLL) and multiple myeloma. Prior to this position, she served as the Global Medical Advisor in Haematology at Novo Nordisk, where she actively participated in developing the global medical strategy and clinical development plans for multiple compounds. Her duties included overseeing clinical trial planning, activities and publications for early development-phase compounds, as well as regulatory filing support and post-approval commitments for late-stage candidates and marketed products. Her experience in these positions included developing and implementing medical programs and participating in the development and review of medical and marketing materials. She played instrumental roles in international advisory boards, organized collaborations with research partners, and networked with key opinion leaders in support of her programs. "I welcome the opportunity to join Immunovaccine, an organization with the potential to profoundly transform the way we approach the treatment of cancer," stated Dr. Rosu. "Immunovaccine is a pioneer in immuno-oncology, initiating one of the first combination trials in the field in 2011, when immuno-oncology was still in its infancy. Today, we understand much more clearly how our immune system has the ability to battle cancers when we can program it with the right instructions. Immunovaccine has developed what I believe to be among the most promising technology and product candidates to achieve just that, and I'm very excited about becoming part of the team who can make it available to patients, safely and effectively, across the world." Prior to her work at Novo Nordisk, Dr. Rosu held various positions of increasing responsibility in organizations including GlaxoSmithKline, Berlex, Celgene, and Lundbeck Canada. Dr. Rosu started her career as Medical Doctor in Europe, practicing family medicine and emergency medicine after an internship in emergency surgery, obstetrics, and pediatrics. She received her Medical Doctor degree in 1995 from the Medical and Pharmaceutical University "Gr.T. Popa" in Iasi, Romania. Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops cancer immunotherapies and infectious disease vaccines based on the Company's DepoVax™ platform, a patented delivery agent that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1/1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as part of a triple combination therapy in ovarian cancer, as well as a Phase 2 study in recurrent lymphoma. The Company is also advancing an infectious disease pipeline, including innovative vaccines for respiratory syncytial virus (RSV), and currently has clinical projects ongoing to assess the potential of DepoVax™ to address malaria and the Zika virus. Connect at www.imvaccine.com. This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management of the Company on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the results and successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by applicable law.


United States, EU, Japan, China, India and Southeast Asia Diagnosis and Treatment of Zika Virus Disease Market This report studies the Global Diagnosis and Treatment of Zika Virus Disease Market, analyzes and researches the Diagnosis and Treatment of Zika Virus Disease development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like  Bharat Biotech  Inovio Pharmaceuticals and GeneOne Life Sciences  Intrexon  Cerus  Sanofi  NewLink Genetics  Immunovaccine  GlaxoSmithKline  ATCC  ZeptoMetrix Market segment by Application, Diagnosis and Treatment of Zika Virus Disease can be split into  Application 1  Application 2  Application 3 United States, EU, Japan, China, India and Southeast Asia Diagnosis and Treatment of Zika Virus Disease Market Size, Status and Forecast 2021  1 Industry Overview of Diagnosis and Treatment of Zika Virus Disease  1.1 Diagnosis and Treatment of Zika Virus Disease Market Overview  1.1.1 Diagnosis and Treatment of Zika Virus Disease Product Scope  1.1.2 Market Status and Outlook  1.2 Global Diagnosis and Treatment of Zika Virus Disease Market Size and Analysis by Regions  1.2.1 United States  1.2.2 EU  1.2.3 Japan  1.2.4 China  1.2.5 India  1.2.6 Southeast Asia  1.3 Diagnosis and Treatment of Zika Virus Disease Market by End Users/Application  1.3.1 Application 1  1.3.2 Application 2  1.3.3 Application 3 2 Global Diagnosis and Treatment of Zika Virus Disease Competition Analysis by Players  2.1 Diagnosis and Treatment of Zika Virus Disease Market Size (Value) by Players (2015-2016)  2.2 Competitive Status and Trend  2.2.1 Market Concentration Rate  2.2.2 Product/Service Differences  2.2.3 New Entrants  2.2.4 The Technology Trends in Future 3 Company (Top Players) Profiles  3.1 Bharat Biotech  3.1.1 Company Profile  3.1.2 Main Business/Business Overview  3.1.3 Products, Services and Solutions  3.1.4 Diagnosis and Treatment of Zika Virus Disease Revenue (Value) (2011-2016)  3.1.5 Recent Developments  3.2 Inovio Pharmaceuticals and GeneOne Life Sciences  3.2.1 Company Profile  3.2.2 Main Business/Business Overview  3.2.3 Products, Services and Solutions  3.2.4 Diagnosis and Treatment of Zika Virus Disease Revenue (Value) (2011-2016)  3.2.5 Recent Developments  3.3 Intrexon  3.3.1 Company Profile  3.3.2 Main Business/Business Overview  3.3.3 Products, Services and Solutions  3.3.4 Diagnosis and Treatment of Zika Virus Disease Revenue (Value) (2011-2016)  3.3.5 Recent Developments  3.4 Cerus  3.4.1 Company Profile  3.4.2 Main Business/Business Overview  3.4.3 Products, Services and Solutions  3.4.4 Diagnosis and Treatment of Zika Virus Disease Revenue (Value) (2011-2016)  3.4.5 Recent Developments  3.5 Sanofi  3.5.1 Company Profile  3.5.2 Main Business/Business Overview  3.5.3 Products, Services and Solutions  3.5.4 Diagnosis and Treatment of Zika Virus Disease Revenue (Value) (2011-2016)  3.5.5 Recent Developments  3.6 NewLink Genetics  3.6.1 Company Profile  3.6.2 Main Business/Business Overview  3.6.3 Products, Services and Solutions  3.6.4 Diagnosis and Treatment of Zika Virus Disease Revenue (Value) (2011-2016)  3.6.5 Recent Developments  3.7 Immunovaccine  3.7.1 Company Profile  3.7.2 Main Business/Business Overview  3.7.3 Products, Services and Solutions  3.7.4 Diagnosis and Treatment of Zika Virus Disease Revenue (Value) (2011-2016)  3.7.5 Recent Developments  3.8 GlaxoSmithKline  3.8.1 Company Profile  3.8.2 Main Business/Business Overview  3.8.3 Products, Services and Solutions  3.8.4 Diagnosis and Treatment of Zika Virus Disease Revenue (Value) (2011-2016)  3.8.5 Recent Developments  3.9 ATCC  3.9.1 Company Profile  3.9.2 Main Business/Business Overview  3.9.3 Products, Services and Solutions  3.9.4 Diagnosis and Treatment of Zika Virus Disease Revenue (Value) (2011-2016)  3.9.5 Recent Developments  3.10 ZeptoMetrix  3.10.1 Company Profile  3.10.2 Main Business/Business Overview  3.10.3 Products, Services and Solutions  3.10.4 Diagnosis and Treatment of Zika Virus Disease Revenue (Value) (2011-2016)  3.10.5 Recent Developments For more information or any query mail at [email protected]


At the close of the Canadian markets on Monday, December 12, 2016, the Toronto Exchange Composite index ended the trading session at 15,287.70, 0.16% lower from its previous closing price. The Healthcare Index was also in the red, closing the day at 67.51, down 1.01%. Active Wall St. has initiated research reports on the following equities: Immunovaccine Inc., (TSX: IMV), Oncolytics Biotech Inc., (TSX: ONC), and Theratechnologies Inc. (TSX: TH). Register with us now for your free membership and research reports at: http://www.activewallst.com/register/. Halifax, Canada headquartered Immunovaccine Inc.'s stock declined 5.41%, to close the day at $0.70. The stock recorded a trading volume of 35,000 shares. Shares of the company, which develops products based on its proprietary vaccine enhancement platform with a primary focus on T cell activating therapies for cancer, are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $0.74 is greater than its 200-day moving average of $0.68. See our research report on IMV.TO at: http://www.activewallst.com/registration-3/?symbol=IMV. Calgary, Canada headquartered Oncolytics Biotech Inc.'s stock advanced 2.17%, to finish Monday's session at $0.23 with a total volume of 168,553 shares traded. Shares of the Company, which focuses on the discovery and development of pharmaceutical products for the treatment of cancers, are trading below its 50-day and 200-day moving averages. Oncolytics Biotech's 200-day moving average of $0.37 is above its 50-day moving average of $0.26. The complimentary research report on ONC.TO at: http://www.activewallst.com/registration-3/?symbol=ONC. On Monday, shares in Montreal, Canada headquartered Theratechnologies Inc. recorded a trading volume of 279,605 shares, which was higher than their three months average volume of 143,655 shares. The stock ended the day 3.83% lower at $2.76. Shares of the Company, which addresses unmet medical needs in metabolic disorders, are trading below its 50-day and 200-day moving averages. The stock's 50-day moving average of $3.13 is above its 200-day moving average of $3.09. Get free access to your research report on TH.TO at: http://www.activewallst.com/registration-3/?symbol=TH. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


The invention compositions comprising a continuous hydrophobic phase and liposomes as a vehicle for delivery of an antigen capable of inducing a cytotoxic T lymphocyte (CTL) response and methods for their use in the treatment of cancer.


The present invention is concerned with vaccines and their preparation. An effective long-term immune response, especially in mammals, can be produced using a vaccine comprising an antigen encapsulated in liposomes, a suitable adjuvant and a carrier comprising a continuous phase of a hydrophobic substance. The vaccine is particularly effective in eliciting the production of antibodies that recognize epitopes of native proteins.


The present invention provides methods for improving the efficacy of a vaccine in the treatment of cancer. The methods of the invention comprise the administration of at least two doses of an agent that interferes with DNA replication prior to vaccination with a survivin vaccine. Also provided are compositions for use in the methods of the invention.


The invention provides compositions comprising liposomes, an antigen capable of inducing a humoral immune response, a carrier comprising a continuous phase of a hydrophobic substance, and an adjuvant that activates or increases the activity of TLR2. The invention also provides uses for such compositions in inducing a humoral response and methods for their use in the treatment of a disease, disorder or ailment ameliorated by a humoral immune response.

Loading Immunovaccine collaborators
Loading Immunovaccine collaborators